Menu visibility control

Video

Events

Startup Surgery

Most Recent

Investments

InMyBag lands £300,000 from investors including onefinestay co-founder

Need to Know

What tech giants Siemens and Apple have planned for post-Brexit Britain

Investments

London-based Vantage Power closes £2.5m pre-Series A

Press Releases

Doctor Care Anywhere selected to join the Mayor of London’s International Business trade mission
Doctor Care Anywhere partners with Aetna International to make its virtual doctor service available 24 hours a day to international patients
Starling Bank unveils beta as it begins roll out to first customers

Life science firms turning to crowdfunding for finance

Life Science
twitterlinkedinFacebookgoogle_plustwitterlinkedinFacebookgoogle_plus

European life sciences companies are increasingly using equity crowdfunding to finance their growth, a new report from market analyst BIOCOM AG has revealed.

The report titled “Analysis of Crowd-based Financing in European Life Sciences” found that UK equity crowdfunding platform SyndicateRoom leads the way when it comes to life science fundraising.

Since its launch two years ago SyndicateRoom has completed 16 life science raises across Europe.

Crowdfunding: what it is and how it works

The found that since 2010, crowdfunding platforms have raised £17m across Europe for 42 life science businesses, with an average raise of around £400K.

Most of this momentum has been in recent years, with nine raises in 2013, 18 raises in 2014 and 13 in the first half of 2015.

SyndicateRoom alone accounts for almost 40% of those raises.

Report author Sandra Wirsching said: “With respect to the high capital demand in the life sciences, it was only a question of time before firms jumped on the bandwagon of crowd financing.

“It is considered as a marketing tool and add-on to other financing instruments.”

“British crowdfunding platforms are amongst the most experienced in Europe. This is mostly due to Britain’s favourable regulatory framework that supports investment in higher-risk technology companies. Furthermore, platforms with strong ties to professional investors, such as SyndicateRoom, fit best to the high capital demand of life science companies.”

SyndicateRoom CEO Gonçalo de Vasconcelos added: “Our unique investor-led model allows our members to co-invest alongside experienced angel investors in highly sophisticated investment opportunities on the same economic terms as the lead investors.

“This is a powerful and successful model for life sciences businesses as they raise capital, as well as a range of other industries, including pharmaceuticals, information technology, property and even movie making.

“We’re particularly proud to lead Europe in life sciences, against a field that includes specialist life sciences platforms. This is a testament to the strength of our model, uniting the crowd with professional investors that often have deep, sector-specific expertise.”

The full BIOCOM report is available here.

 

Enter your email address to receive updates straight to your inbox

* indicates required
Send me news on...
twitterlinkedinFacebookgoogle_plustwitterlinkedinFacebookgoogle_plus

Editor's picks

InMyBag

InMyBag lands £300,000 from investors including onefinestay co-founder
posted 10 hours ago

Brexit

What tech giants Siemens and Apple have planned for post-Brexit Britain
posted 13 hours ago

161014 Vantage Power: Reading Buses, Live trial.

London-based Vantage Power closes £2.5m pre-Series A
posted 15 hours ago

Scotland

Edinburgh-based Reactec closes £700,000 round led by Archangels
posted 17 hours ago

Edinburgh

Edinburgh’s tech accelerator Seed Haus launches £300,000 investment fund
posted 20 hours ago

Bristol - South West of England

Top tech hubs in the South West of England
posted on March 27, 2017